Application of Lipidomics in Psychiatry: Plasma-Based Potential Biomarkers in Schizophrenia and Bipolar Disorder
Open accessAbstract
In this study, we obtained a lipidomic profile of plasma samples from drug-naïve patients with schizophrenia (SZ) and bipolar disorder (BD) in comparison to healthy controls. The sample cohort consisted of 30 BD and 30 SZ patients and 30 control individuals. An untargeted lipidomics strategy using liquid chromatography coupled with high-resolution mass spectrometry was employed to obtain the lipid profiles. Data were preprocessed, then univariate (t-test) and multivariate (principal component analysis and orthogonal partial least squares discriminant analysis) statistical tools were applied to select differential lipids, which were putatively identified. Afterward, multivariate receiver operating characteristic tests were performed, and metabolic pathway networks were constructed, considering the differential lipids. Our results demonstrate alterations in distinct lipid pathways, especially in glycerophospholipids, sphingolipids and glycerolipids, between SZ and BD patients. The results obtained in this study may serve as a basis for differential diagnosis, which is crucial for effective treatment and improving the quality of life of patients with psychotic disorders.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nine studies evaluated broad panels of different lipid markers in patients with SCZ and detected statistical differences in fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.
“Nine studies evaluated the broad panels of different lipid markers in patients with SCZ [31,34,40,41,42,43,44,45,46] and detected statistical differences in the following lipid classes: fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888 · see citing works
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 2× · see citing works
“Legend: SZ = schizophrenia; BD = bipolar disorder; CT = healthy controls; M = male; F = female; SD = standard deviation; PANSS = Positive and Negative Syndrome Scale; HAM-D = Hamilton Depression Rating Scale; YMRS = Young Mania Rating Scale.”
MethodThe Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · see citing works
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744 · see citing works
Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R. A., & Siuzdak, G. E. (2006) · Analytical Chemistry · doi:10.1021/ac051437y · Cited by 5,296 · see citing works
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders
Bell, C. C. (1994) · JAMA · doi:10.1001/jama.1994.03520100096046 · Cited by 2,608 · see citing works
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710 · see citing works
Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sby058 · Cited by 1,647 · see citing works
Pang, Z., Zhou, G., Ewald, J., Chang, L., Haçarız, O., Basu, N., & Xia, J. (2022) · Nature Protocols · doi:10.1038/s41596-022-00710-w · Cited by 1,458 · see citing works
Kuhl, C., Tautenhahn, R., Böttcher, C., Larson, T. R., & Neumann, S. (2011) · Analytical Chemistry · doi:10.1021/ac202450g · Cited by 1,208 · see citing works
Sud, M., Fahy, E., Cotter, D., Azam, K., Vadivelu, I., Burant, C., Edison, A. S., Fiehn, O., Higashi, R. M., Nair, K. S., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1042 · Cited by 1,008 · see citing works
Bipolar disorder diagnosis: challenges and future directions
Phillips, M. L., & Kupfer, D. J. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60989-7 · Cited by 684 · see citing works
Increased cortical kynurenate content in schizophrenia
Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C. A., & Roberts, R. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01078-2 · Cited by 590 · see citing works
Epidemiology and risk factors for bipolar disorder
Rowland, T., & Marwaha, S. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318769235 · Cited by 513 · see citing works
Alonso, J., Petukhova, M., Vilagut, G., Chatterji, S., Heeringa, S., Üstün, T. B., Alhamzawi, A. O., Viana, M. C., Angermeyer, M., Bromet, E., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.101 · Cited by 482 · see citing works
Yuan, N., Chen, Y., Xia, Y., Dai, J., & Liu, C. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0570-y · Cited by 428 · see citing works
IPO: a tool for automated optimization of XCMS parameters
Libiseller, G., Dvorzak, M., Kleb, U., Gander, E., Eisenberg, T., Madeo, F., Neumann, S., Trausinger, G., Sinner, F. M., Pieber, T. R., et al. (2015) · BMC Bioinformatics · doi:10.1186/s12859-015-0562-8 · Cited by 343 · see citing works
Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients
Yao, J. K., Leonard, S. S., & Reddy, R. D. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00095-x · Cited by 290 · see citing works
Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?
Ross, B. M., Seguin, J., & Sieswerda, L. E. (2007) · Lipids in Health and Disease · doi:10.1186/1476-511x-6-21 · Cited by 275 · see citing works
Role Of Lipids In Brain Injury And Diseases
Rao, A. M., & Hatcher, J. F. (2007) · Future Lipidology · doi:10.2217/17460875.2.4.403 · Cited by 270 · see citing works
Veselkov, K., Karstens, L., Masson, P., Robinette, S. L., Want, E. J., Li, J. V., Barton, R. H., Boursier-Neyret, C., Walther, B., Ebbels, T. M. D., et al. (2011) · Analytical Chemistry · doi:10.1021/ac201065j · Cited by 267 · see citing works
Basu, S., Duren, W. L., Evans, C. R., Burant, C., Michailidis, G. C., & Karnovsky, A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx012 · Cited by 267 · see citing works
Arvindakshan, M., Sitasawad, S. L., Debsikdar, V. B., Ghate, M. R., Evans, D. R., Horrobin, D. F., Bennett, C. N., Ranjekar, P. K., & Mahadik, S. P. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01443-9 · Cited by 232 · see citing works
Gao, J., Tarcea, V. G., Karnovsky, A., Mirel, B. R., Weymouth, T. E., Beecher, C., Cavalcoli, J. D., Athey, B. D., Omenn, G. S., Burant, C., et al. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq048 · Cited by 231 · see citing works
Gattaz, W. F., Köllisch, M., Thuren, T. Y., et al. (1987) · Biological Psychiatry · doi:10.1016/0006-3223(87)90164-8 · Cited by 216 · see citing works
Self-citationComan, C., Solari, F. A., Hentschel, A., Sickmann, A., Zahedi, R. P., & Ahrends, R. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.053702 · Cited by 168 · see citing works
Increased platelet phospholipase A2 activity in schizophrenia
Gattaz, W. F. (1995) · Schizophrenia Research · doi:10.1016/0920-9964(94)00060-l · Cited by 164 · see citing works
Self-citationCEU Mass Mediator 3.0: A Metabolite Annotation Tool
Gil-de-la-Fuente, A., Godzień, J., Saugar, S., García-Carmona, R., Badran, H., Wishart, D. S., Barbas, C., & Otero, A. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00720 · Cited by 163 · see citing works
ECNP consensus meeting. Bipolar depression. Nice, March 2007
Goodwin, G. M., Anderson, I. M., Arango, C., Bowden, C. L., Henry, C., Mitchell, P. B., Nolen, W. A., Vieta, E., & Wïttchen, H. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.03.003 · Cited by 150 · see citing works
Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder
Brunkhorst-Kanaan, N., Klatt‐Schreiner, K., Hackel, J., Schröter, K., Trautmann, S., Hahnefeld, L., Wicker, S., Reif, A., Thomas, D., Geißlinger, G., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.002 · Cited by 132 · see citing works
McEvoy, J., Baillie, R. A., Zhu, H., Buckley, P., Keshavan, M. S., Nasrallah, H. A., Dougherty, G. G., Yao, J. K., & Kaddurah-Daouk, R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068717 · Cited by 127 · see citing works
Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders
Sethi, S., & Brietzke, E. M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv096 · Cited by 122 · see citing works
Epidemiology and risk factors of schizophrenia.
Janoutová, J., Janácková, P., Šerý, O., et al. (2016) · PubMed · Cited by 109 · see citing works
Therapeutic use of omega-3 fatty acids in bipolar disorder
Balanzá‐Martínez, V., Fries, G. R., Colpo, G. D., Silveira, P. P., Portella, A. K., Tabarés‐Seisdedos, R., & Kapczinski, F. P. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.42 · Cited by 104 · see citing works
Tessier, C., Sweers, K., Frajerman, A., Bergaoui, H., Ferreri, F., Delva, C., Lapidus, N., Lamazière, A., Roiser, J. P., Hert, M. A. F. D., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.142 · Cited by 101 · see citing works
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95 · see citing works
Biomarkers for bipolar disorder: current status and challenges ahead
Teixeira, A. L., Colpo, G. D., Fries, G. R., Bauer, I. E., & Selvaraj, S. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1550361 · Cited by 95 · see citing works
Knowledge-based metabolite annotation tool: CEU Mass Mediator
Gil-de-la-Fuente, A., Godzień, J., Fernández‐López, M., Rupérez, F. J., Barbas, C., & Otero, A. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.02.046 · Cited by 90 · see citing works
Chiappelli, J., Pocivavsek, A., Nugent, K. L., Notarangelo, F. M., Kochunov, P. V., Rowland, L. M., Schwarcz, R. M., & Hong, L. E. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.243 · Cited by 88 · see citing works
Smesny, S., Milleit, B., Hipler, U. ‐., Milleit, C., Schäfer, M. R., Klier, C. M., Holub, M., Holzer, I., Berger, G. E., Otto, M., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.7 · Cited by 79 · see citing works
Ghosh, S., Dyer, R., & Beasley, C. L. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.08.009 · Cited by 56 · see citing works
A preliminary study of bipolar disorder type I by mass spectrometry-based serum lipidomics
Ribeiro, H. C., Klassen, A., Pedrini, M., Carvalho, M. S., Rizzo, L. B., Noto, M. N., Zeni‐Graiff, M., Sethi, S., Fonseca, F. A. H., Tasić, L., et al. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.08.039 · Cited by 45 · see citing works
Self-citationTasić, L., Pontes, J. G. M., Carvalho, M. S., Cruz, G. C. F., Mas, C. D., Sethi, S., Pedrini, M., Rizzo, L., Zeni-Graiff, M., Asevedo, E., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2016.12.024 · Cited by 39 · see citing works
Increased PLA2 activity in the hippocampus of patients with temporal lobe epilepsy and psychosis
Gattaz, W. F., Valente, K. D. R., Raposo, N. R. B., et al. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.07.005 · Cited by 38 · see citing works
Self-citationMetabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia
Quintero, M., Stanisic, D., Cruz, G., Pontes, J. G. M., Costa, T. B. B. C., & Tasic, L. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_14 · Cited by 32 · see citing works
Burton, T. C. J., Lv, N., Tsai, P., Bernabé, B. P., Tussing-Humphreys, L. M., Xiao, L., Pandey, G. N., Wu, Y., Ajilore, O., & Ma, J. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.01.018 · Cited by 28 · see citing works
Ayano, G. (2016) · SOJ Psychology · doi:10.15226/2374-6874/3/2/00131 · Cited by 24 · see citing works
Maternal serum docosahexaenoic acid and schizophrenia spectrum disorders in adult offspring
Harper, K. N., Hibbeln, J. R., Deckelbaum, R., Quesenberry, C. P., Schaefer, C. A., & Brown, A. S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.01.009 · Cited by 23 · see citing works
Guo, L., Zhang, T., Li, R., Cui, Z.-Q., Du, J., Yang, J.-B., Xue, F., Chen, Y., Tan, Q.-R., & Peng, Z. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.802710 · Cited by 23 · see citing works
Wang, F., Guo, L., Zhang, T., Cui, Z., Wang, J., Zhang, C., Xue, F., Zhou, C., Li, B., Tan, Q., et al. (2022) · Medicina · doi:10.3390/medicina58111509 · Cited by 18 · see citing works
Brum, M., Nieberler, M., Kehrwald, C., Knopf, K., Brunkhorst-Kanaan, N., Etyemez, S., Allers, K. A., Bittner, R. A., Slattery, D. A., McNeill, R. V., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2023.2169348 · Cited by 16 · see citing works
Ribeiro, H. C., Sen, P., Dickens, A. M., Cruz, E. C. S., Orešič, M., & Sussulini, A. (2022) · Metabolomics · doi:10.1007/s11306-022-01924-5 · Cited by 12 · see citing works
Self-citationLiu, J.-C., Yu, H., Li, R., Zhou, C., Shi, Q., Guo, L. Q., & He, H. (2023) · Medicina · doi:10.3390/medicina59020413 · Cited by 8 · see citing works
Gattaz, W. F., Brunner, J., Schmitt, A., et al. (1995) · Springer eBooks · doi:10.1007/978-3-642-79429-2_13 · Cited by 7 · see citing works
Self-citationPlasma metabolites in first episode psychoses
Costa, A. C., Joaquim, H. P. G., Talib, L. L., Serpa, M. H., Zanetti, M. V., & Gattaz, W. F. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2018.11.010 · Cited by 7 · see citing works
Self-citationGattaz, W. F., Brunner, J., Schmitt, A., et al. (1994) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-2007-1002352 · Cited by 6 · see citing works
Self-citationIncreased PLA2 activity in individuals at ultra-high risk for psychosis
Talib, L. L., Costa, A. C., Joaquim, H. P. G., Pereira, C. A. C., van de Bilt, M. T., Loch, A. A., & Gattaz, W. F. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01246-y · Cited by 6 · see citing works
Self-citationLin, S., Li, P., Qin, J., Liu, Q., Zhang, J., Meng, N., Jia, C., Zhu, K., Lv, D., Sun, L., et al. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117252 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- [11]Ayano G. Schizophrenia: A concise overview of etiology, epidemiology diagnosis and management: Review of Literatures J. Schizophr. Res. 2016 3 2 7
- [19]Skinner E.R. Brain Lipids and Disorders in Biological Psychiatry Elsevier Science London, UK 2002 Volume 35
- [28]Gorgens K.A. Structured clinical interview for DSM-IV (SCID-I/SCID-II) Encyclopedia of Clinical Neuropsychology Springer New York, NY, USA 2011 2410 2417
Cited by
Sorted by citations
Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36 · see citing works
- Authors
- Costa, A., Riça, L., van de Bilt, M., Zandonadi, F., Gattaz, W., Talib, L., & Sussulini, A.
- Affiliations
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Laboratory of Neuroscience (LIM-27), Department and Institute of Psychiatry, University of Sao Paulo Medical School, Sao Paulo 05403903, Brazil
- Corresponding author
- Sussulini, Alessandra
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2023-04-27
- Volume
- 13
- Issue
- 5
- Pages
- 600
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC10222421
- OpenAlex
- W4367181572
- Cited by
- 25
- References
- 58
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 8 · 2023: 2
- FWCI
- 2.23
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo—FAPESP (2017/26291-2, 2018/01525-3, 2014/50873-3, 2014/50867-3, 306662/2022-1)
- Instituto Nacional de Biomarcadores em Neuropsiquiatria (2017/26291-2, 2018/01525-3, 2014/50873-3, 2014/50867-3, 306662/2022-1)
- Instituto Nacional de Ciência e Tecnologia de Bioanalítica (2017/26291-2, 2018/01525-3, 2014/50873-3, 2014/50867-3, 306662/2022-1)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPq (2017/26291-2, 2018/01525-3, 2014/50873-3, 2014/50867-3, 306662/2022-1)
- Associação Beneficente Alzira Denise Hertzog da Silva (ABADHS) (2017/26291-2, 2018/01525-3, 2014/50873-3, 2014/50867-3, 306662/2022-1)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- lipidomics, schizophrenia, bipolar disorder, plasma lipids, biomarkers, differential lipids, glycerophospholipids, sphingolipids, glycerolipids, differential diagnosis, psychosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
